J
Julie C. Locklear
Researcher at Merck Serono
Publications - 38
Citations - 1409
Julie C. Locklear is an academic researcher from Merck Serono. The author has contributed to research in topics: Quetiapine & Quetiapine Fumarate. The author has an hindex of 13, co-authored 38 publications receiving 1302 citations. Previous affiliations of Julie C. Locklear include AstraZeneca.
Papers
More filters
Journal ArticleDOI
Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia
TL;DR: This study showed a direct correlation between estimated partial compliance and hospitalization risk among patients with schizophrenia across a continuum of compliance behavior.
Journal ArticleDOI
A systematic review of the evidence of the burden of bipolar disorder in Europe.
TL;DR: Bipolar disorder is a major and underestimated health problem in Europe, and a number of issues impact on the economic burden of the disease, such as comorbidities, suicide, early death, unemployment or underemployment.
Journal ArticleDOI
Treatment options for bipolar depression: a systematic review of randomized, controlled trials.
Eduard Vieta,Julie C. Locklear,Oliver Günther,Mattias Ekman,Carolin Miltenburger,Mary Lou Chatterton,Mikael Aström,Björn Paulsson +7 more
TL;DR: Variability in efficacy exists between treatments of bipolar depression, and quetiapine and the olanzapine-fluoxetine combination showed the greatest symptomatic improvement.
Journal ArticleDOI
Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder : a meta-analysis of randomized controlled trials
Eduard Vieta,Oliver Günther,Julie C. Locklear,Mattias Ekman,Carolin Miltenburger,Mary Lou Chatterton,Mikael Aström,Björn Paulsson +7 more
TL;DR: The efficacy of lithium and divalproex has been confirmed, but newer therapies, such as a number of atypical antipsychotics were also shown to be effective in bipolar disorder.
Journal ArticleDOI
Humanistic and economic burden of generalized anxiety disorder in North America and Europe
Dennis A. Revicki,Karin Travers,Kathleen W. Wyrwich,Henrik Svedsater,Julie C. Locklear,Maria Stoeckl Mattera,David V. Sheehan,Stuart Montgomery +7 more
TL;DR: GAD is associated with significant burden on patient functioning and well-being, leading to increased health care utilization and medical costs, and patients with GAD are often suboptimally treated, which adds to the HRQL burden of this disorder.